Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Amundi

Amundi reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 19.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,795 shares of the company’s stock after selling 11,987 shares during the period. Amundi’s holdings in Intellia Therapeutics were worth $587,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in NTLA. ARK Investment Management LLC increased its stake in shares of Intellia Therapeutics by 2.3% in the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after buying an additional 280,946 shares during the last quarter. State Street Corp lifted its holdings in Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after purchasing an additional 780,754 shares during the period. Geode Capital Management LLC lifted its holdings in Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after purchasing an additional 49,367 shares during the period. FMR LLC lifted its holdings in Intellia Therapeutics by 5.0% in the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company’s stock valued at $48,077,000 after acquiring an additional 111,104 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in Intellia Therapeutics by 33.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock valued at $21,118,000 after acquiring an additional 257,700 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company’s stock.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $8.70 on Friday. The firm’s fifty day moving average is $10.11 and its two-hundred day moving average is $14.33. The firm has a market cap of $900.60 million, a price-to-earnings ratio of -1.60 and a beta of 1.97. Intellia Therapeutics, Inc. has a one year low of $8.30 and a one year high of $28.54.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. BMO Capital Markets dropped their target price on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, January 10th. Chardan Capital decreased their target price on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Citigroup increased their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.56.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.